🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07440797
Starting soon Not applicable

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

NCT07440797 · tracked via the Priya Life Science USA tracker
Sponsor
Laboratoires URGO
Phase
Not applicable
Started
2026-03
Last updated
2026-03-04

Condition(s) studied

Venous Leg Ulcer (VLU)

Investigational drug(s) / intervention(s)

Saline solutionVashe solution

Saline solution: randomization to saline solution group for local management of venous or mixed leg ulcers

Vashe solution: randomisation to Vashe solution group for local management of venous or mixed leg ulcers

Study summary

Evaluation of the efficacy (reduction of inflammatory signs suggesting a local infection) and tolerance (emergence and nature of adverse event) of Vashe solution vs Saline solution in the treatment of venous or mixed leg ulcers presenting inflammatory signs suggesting heavy bacterial load

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Adult patient, at least 18 years of age or older who has provided free, written, and informed consent, * Patient who has already worn compression therapy in the past and agrees to wear the two-layer compression system during the whole treatment period, * Patient presenting a venous or mixed leg ulcer predominantly of venous origin (ABPI between ≥0.8≤1.3, * Leg ulcer presenting at least 3 inflammatory signs (e.g pain, erythema...) * Target leg ulcer located at least 3 cm from the edge of another wound. Exclusion Criteria: * Pregnant or breastfeeding patient, * Patient already participating in another clinical trial, except observational trial * Patient with epifascial arterial bypass (superficial arterial bypass) * Patient suffering from phlegmatia coerulea dolens, septic phlebitis, acute deep vein thrombosis (DVT), defined as the first 10 days from onset of symptoms, or any DVT for which compression is considered by the Investigator to be contraindicated. * Patient receiving or having received systemic antibiotics within the ten days prior to inclusion in the investigation, regardless of therapeutic class or indication, * Cancerous wound.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Comprehensive Wound Healing Center and Hyperbarics, Northwell Health New York New York

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07440797 on ClinicalTrials.gov ↗ ← All trials in the USA